Business Context and Reporting Period
This Form 8-K was filed by ADVENTRX Pharmaceuticals, Inc. on March 7, 2012. The filing serves to announce the company's financial results for the three months and the full year ended December 31, 2011. The registrant is incorporated in Delaware with principal executive offices in San Diego, California.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the body of this 8-K document.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the text provided. It solely references the issuance of a press release containing the comparative financial results.
Guidance, Outlook, and Risks
The document does not contain management commentary, forward-looking guidance, risk factors, or contingencies. It strictly functions as a notification of the press release regarding the 2011 financial results.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 7, 2012) for actual revenue, net loss, and cash position figures.
- Verify the specific operational milestones or clinical trial updates mentioned in the referenced press release.
- Confirm the company's liquidity status and runway as detailed in the full financial statements referenced in the press release.